5. References

  1. Deming P. Viral Hepatitis. In: DiPiro J, Yee G, Posey M, et al. Pharmacotherapy: a pathophysiologic approach, 11e New York, NY: McGraw-Hill. Available from: https://accesspharmacy-mhmedical-com.ezproxy.lib.utexas.edu/content.aspx?bookid=2577&sectionid=224357874#1182438955. Accessed 10 June 2022. 
  2. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc; 2022. Available at: http://www.clinicalpharmacology.com. Accessed June 11, 2022.
  3. IBM Micromedex® DRUGDEX® (electronic version). Truven Health Analytics, Greenwood Village, Colorado, USA. Available at: http://www.micromedexsolutions.com.libproxy.uthscsa.edu/ (cited: June 13th 2022). 
  4. Sofosbuvir (Sovaldi®) package insert. Gilead Sciences, Inc., Updated 5 March 2020.
  5. Ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets (Viekira Pak®) package insert. AbbVie Inc., November 2017.
  6. Ledipasvir and sofosbuvir (Harvoni®) package insert. Gilead Sciences, Inc., Updated 5 March 2020.
  7. Elbasvir/grazoprevir (Zepatier®) package insert. Merck & CO., Inc., Updated 19 December 2021.
  8. Sofosbuvir/velpatasvir (Epclusa®) package insert. Gilead Sciences, Inc., Updated 27 April 2022.
  9. Sofosbuvir/velpatasvir/voxilaprevir (Vosevi®) package insert. Gilead Sciences, Inc., Updated 15 November 2019.
  10. Glecaprevir/pibrentasvir (Mavyret™) package insert. AbbVie Inc., Updated 28 September 2021.
  11. Ribavirin (Rebetol®) package insert. Merck & Co., Inc., March 2022.
  12. AASLD-IDSA. Recommendations for testing, managing, and treating hepatitis C. http://www.hcvguidelines.org. Accessed 28 June 2022. 
  13. Hepatitis C guidance 2018 update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection. Clinical Infectious Diseases 2018; 67(10): 1477-92.